57 related articles for article (PubMed ID: 17968681)
1. Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer.
Lin Y; Yang Q
Anticancer Drugs; 2024 Feb; 35(2):209-217. PubMed ID: 37948339
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
[TBL] [Abstract][Full Text] [Related]
3. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Muñoz R; Hileeto D; Cruz-Muñoz W; Wood GA; Xu P; Man S; Viloria-Petit A; Kerbel RS
PLoS One; 2019; 14(9):e0222580. PubMed ID: 31536574
[TBL] [Abstract][Full Text] [Related]
4. High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.
Sakaguchi I; Motohara T; Saito F; Takaishi K; Fukumatsu Y; Tohya T; Shibata S; Mimori H; Tashiro H; Katabuchi H
J Gynecol Oncol; 2015 Jul; 26(3):193-200. PubMed ID: 25686399
[TBL] [Abstract][Full Text] [Related]
5. Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladder.
Harada K; Miyake H; Terakawa T; Fujisawa M
Curr Urol; 2012 May; 6(1):27-32. PubMed ID: 24917706
[TBL] [Abstract][Full Text] [Related]
6. Treatment results of incomplete chemoradiotherapy in locally advanced cervical cancer.
Gao Y; Gao F; Liu Z; Song LP
Onco Targets Ther; 2013; 6():297-302. PubMed ID: 23579439
[TBL] [Abstract][Full Text] [Related]
7. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
8. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.
Langer CJ
Lung Cancer; 2001 Nov; 34(2):297-303. PubMed ID: 11679189
[TBL] [Abstract][Full Text] [Related]
9. UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Nagai N; Mukai K; Hirata E; Jin HH; Komatsu M; Yunokawa M
Med Oncol; 2008; 25(2):214-21. PubMed ID: 17968681
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y
Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367
[TBL] [Abstract][Full Text] [Related]
11. [Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Basaki Y; Yonekura K; Chikahisa L; Okabe S; Hashimoto A; Miyadera K; Aoyagi K; Yamada Y
Gan To Kagaku Ryoho; 2000 Jan; 27(1):93-8. PubMed ID: 10660738
[TBL] [Abstract][Full Text] [Related]
12. UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Basaki Y; Aoyagi K; Chikahisa L; Miyadera K; Hashimoto A; Yonekura K; Okabe S; Shibata J; Wierzba K; Yamada Y
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):68-71. PubMed ID: 11098498
[TBL] [Abstract][Full Text] [Related]
13. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
[TBL] [Abstract][Full Text] [Related]
14. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Tsuji W; Ishiguro H; Tanaka S; Takeuchi M; Ueno T; Toi M
Int J Clin Oncol; 2014; 19(3):452-9. PubMed ID: 23739924
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
